Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WHO Closer To FDA Approval For Malaria Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA has been holding the world body to the same standards it uses for a regular drug review, resulting in many years of delay in bringing artesunate rectal suppositories to market - but the Anti-Infective Drugs Advisory Committee has given a partial endorsement.

You may also be interested in...



Amivas’ Malaria Drug Approval Brings Orphan Exclusivity, But Priority Review Voucher Status Unclear

Amivas requested a US tropical disease PRV for intravenous artesunate but FDA has not yet made a decision on eligibility; approval appears to block La Jolla’s competing product, currently under review, for seven years.

Synthetic Cell Technology Could Benefit Vaccine Production, Venter Says

J. Craig Venter's synthetic cell may dramatically speed up vaccine production, he told a Congressional committee

Synthetic Cell Technology Could Benefit Vaccine Production, Venter Says

J. Craig Venter's synthetic cell may dramatically speed up vaccine production, he told a Congressional committee

Topics

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel